Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: Assessment of different filter systems

Andreas Koster, Frank Merkle, Roland Hansen, Matthias Loebe, H. Herrmann Kuppe, Roland Hetzer, George J. Crystal, Fritz Mertzlufft

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Recombinant hirudin (r-hirudin) is being used increasingly in patients with heparin-induced thrombocytopenia type II. Renal failure has been demonstrated to prolong the half-life of r-hirudin and to cause bleeding in patients who have undergone cardiopulmonary bypass (CPB). We assessed the ability of different filter systems for modified ultrafiltration to eliminate r-hirudin in vitro using simulated CPB. r-Hirudin concentration was measured (chromogenic laboratory standard plus ecarin clotting time) before and after filtration, and its elimination was calculated using both controlled system flow and arterial inflow (separate pump). Four hemofilters (Renoflow II, Baxter; Arylane H4, Cobe; Ultraflux AV 600, Fresenius; and BCS 110 Plus, Iostra) and two plasmapheresis filter systems (ASAHI Plasmaflow OP, Diamed; and PF 2000 N, Gambro) were assessed (5 filters of each brand = 30 filters) in a closed in vitro CPB system applying conditions usually occurring during CPB. Ten plasmapheresis filters showed a greater ability than 20 hemofilters to eliminate r-hirudin (60%-70% vs 15%-42%) within the shortest time (80 vs 180 s). Among the four hemofilter systems, the Arylane H4 filter provided the most effective (42%) r-hirudin elimination. Elimination of r-hirudin was markedly improved using plasmapheresis systems, compared with hemofilter systems. Our findings may be relevant to patients with impaired renal function, who have been administered r-hirudin during CPB.

Original languageEnglish (US)
Pages (from-to)265-269
Number of pages5
JournalAnesthesia and Analgesia
Volume91
Issue number2
StatePublished - 2000
Externally publishedYes

Fingerprint

Hirudins
Ultrafiltration
Cardiopulmonary Bypass
Plasmapheresis
Thrombocytopenia
Renal Insufficiency
Half-Life
Heparin
Hemorrhage
Kidney

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass : Assessment of different filter systems. / Koster, Andreas; Merkle, Frank; Hansen, Roland; Loebe, Matthias; Kuppe, H. Herrmann; Hetzer, Roland; Crystal, George J.; Mertzlufft, Fritz.

In: Anesthesia and Analgesia, Vol. 91, No. 2, 2000, p. 265-269.

Research output: Contribution to journalArticle

Koster, A, Merkle, F, Hansen, R, Loebe, M, Kuppe, HH, Hetzer, R, Crystal, GJ & Mertzlufft, F 2000, 'Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: Assessment of different filter systems', Anesthesia and Analgesia, vol. 91, no. 2, pp. 265-269.
Koster, Andreas ; Merkle, Frank ; Hansen, Roland ; Loebe, Matthias ; Kuppe, H. Herrmann ; Hetzer, Roland ; Crystal, George J. ; Mertzlufft, Fritz. / Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass : Assessment of different filter systems. In: Anesthesia and Analgesia. 2000 ; Vol. 91, No. 2. pp. 265-269.
@article{b43b79fcb31040feafa537104ac4a643,
title = "Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: Assessment of different filter systems",
abstract = "Recombinant hirudin (r-hirudin) is being used increasingly in patients with heparin-induced thrombocytopenia type II. Renal failure has been demonstrated to prolong the half-life of r-hirudin and to cause bleeding in patients who have undergone cardiopulmonary bypass (CPB). We assessed the ability of different filter systems for modified ultrafiltration to eliminate r-hirudin in vitro using simulated CPB. r-Hirudin concentration was measured (chromogenic laboratory standard plus ecarin clotting time) before and after filtration, and its elimination was calculated using both controlled system flow and arterial inflow (separate pump). Four hemofilters (Renoflow II, Baxter; Arylane H4, Cobe; Ultraflux AV 600, Fresenius; and BCS 110 Plus, Iostra) and two plasmapheresis filter systems (ASAHI Plasmaflow OP, Diamed; and PF 2000 N, Gambro) were assessed (5 filters of each brand = 30 filters) in a closed in vitro CPB system applying conditions usually occurring during CPB. Ten plasmapheresis filters showed a greater ability than 20 hemofilters to eliminate r-hirudin (60{\%}-70{\%} vs 15{\%}-42{\%}) within the shortest time (80 vs 180 s). Among the four hemofilter systems, the Arylane H4 filter provided the most effective (42{\%}) r-hirudin elimination. Elimination of r-hirudin was markedly improved using plasmapheresis systems, compared with hemofilter systems. Our findings may be relevant to patients with impaired renal function, who have been administered r-hirudin during CPB.",
author = "Andreas Koster and Frank Merkle and Roland Hansen and Matthias Loebe and Kuppe, {H. Herrmann} and Roland Hetzer and Crystal, {George J.} and Fritz Mertzlufft",
year = "2000",
language = "English (US)",
volume = "91",
pages = "265--269",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass

T2 - Assessment of different filter systems

AU - Koster, Andreas

AU - Merkle, Frank

AU - Hansen, Roland

AU - Loebe, Matthias

AU - Kuppe, H. Herrmann

AU - Hetzer, Roland

AU - Crystal, George J.

AU - Mertzlufft, Fritz

PY - 2000

Y1 - 2000

N2 - Recombinant hirudin (r-hirudin) is being used increasingly in patients with heparin-induced thrombocytopenia type II. Renal failure has been demonstrated to prolong the half-life of r-hirudin and to cause bleeding in patients who have undergone cardiopulmonary bypass (CPB). We assessed the ability of different filter systems for modified ultrafiltration to eliminate r-hirudin in vitro using simulated CPB. r-Hirudin concentration was measured (chromogenic laboratory standard plus ecarin clotting time) before and after filtration, and its elimination was calculated using both controlled system flow and arterial inflow (separate pump). Four hemofilters (Renoflow II, Baxter; Arylane H4, Cobe; Ultraflux AV 600, Fresenius; and BCS 110 Plus, Iostra) and two plasmapheresis filter systems (ASAHI Plasmaflow OP, Diamed; and PF 2000 N, Gambro) were assessed (5 filters of each brand = 30 filters) in a closed in vitro CPB system applying conditions usually occurring during CPB. Ten plasmapheresis filters showed a greater ability than 20 hemofilters to eliminate r-hirudin (60%-70% vs 15%-42%) within the shortest time (80 vs 180 s). Among the four hemofilter systems, the Arylane H4 filter provided the most effective (42%) r-hirudin elimination. Elimination of r-hirudin was markedly improved using plasmapheresis systems, compared with hemofilter systems. Our findings may be relevant to patients with impaired renal function, who have been administered r-hirudin during CPB.

AB - Recombinant hirudin (r-hirudin) is being used increasingly in patients with heparin-induced thrombocytopenia type II. Renal failure has been demonstrated to prolong the half-life of r-hirudin and to cause bleeding in patients who have undergone cardiopulmonary bypass (CPB). We assessed the ability of different filter systems for modified ultrafiltration to eliminate r-hirudin in vitro using simulated CPB. r-Hirudin concentration was measured (chromogenic laboratory standard plus ecarin clotting time) before and after filtration, and its elimination was calculated using both controlled system flow and arterial inflow (separate pump). Four hemofilters (Renoflow II, Baxter; Arylane H4, Cobe; Ultraflux AV 600, Fresenius; and BCS 110 Plus, Iostra) and two plasmapheresis filter systems (ASAHI Plasmaflow OP, Diamed; and PF 2000 N, Gambro) were assessed (5 filters of each brand = 30 filters) in a closed in vitro CPB system applying conditions usually occurring during CPB. Ten plasmapheresis filters showed a greater ability than 20 hemofilters to eliminate r-hirudin (60%-70% vs 15%-42%) within the shortest time (80 vs 180 s). Among the four hemofilter systems, the Arylane H4 filter provided the most effective (42%) r-hirudin elimination. Elimination of r-hirudin was markedly improved using plasmapheresis systems, compared with hemofilter systems. Our findings may be relevant to patients with impaired renal function, who have been administered r-hirudin during CPB.

UR - http://www.scopus.com/inward/record.url?scp=0033863121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033863121&partnerID=8YFLogxK

M3 - Article

C2 - 10910829

AN - SCOPUS:0033863121

VL - 91

SP - 265

EP - 269

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 2

ER -